NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

“Centerpiece”

Was intentionally made ambiguous in terms of timing. Aka: Toying with shareholders
regarding when (at what phase) it would be employed in “scale up” (Aka at or after approval) It’s the kind of language where they think they’re clever and investors get teed off due to NWBO’s ambiguity. (They get mad, because people think it might be used as another delay tactic)

One is not supposed to be murky in 10qs. Your question implies it’s ambiguous to you as well.

My opinion. Post approval scale up. But I’m just guessing because their filing is unreasonably ambiguous, and if I recall, DI apparently put it in a text that they would begin with the artisan method. My recollection is he was adamant.